EGFR and non-small cell lung carcinoma: Phase I data from a first-in-human study showed an ORR of 61% (95% CI, 43.6–77.8) and a disease control rate (DCR) of 91.2% (76.3–98.1) in heavily treated NSCLC EGFR-mutated cases (n = 34).